Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
NPR · 36 days ago
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
Continue reading at NPR →













